Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.
Related Articles
Federal judge tosses Blue Cross Blue Shield of Louisiana lawsuit, another loss for Medicare Advantage insurers
The Medicare Advantage industry has aggressively sued the federal government to overturn reduced quality ratings and keep billions of taxpayer-funded bonuses.
Ending the federal LGBTQ+ suicide prevention line is a public health failure
Ending the federal LGBTQ+ suicide prevention line is a public health failure, write two leaders in prevention and crisis response.
US drops charges against doctor accused of destroying Covid vaccines
US Attorney General Pam Bondi said the doctor ‘gave patients a choice when the federal government refused to do so’.
Fundraising in academia and the Epstein problem
Philanthropy can provide enormous benefits, and should be encouraged, but it can also create terrible reputational damage when a donor turns out to be toxic,…
UnitedHealth’s Campaign to Quiet Critics
The company has invoked the murder of an executive last year to complain about coverage in news outlets, on streaming services and on social media.
UnitedHealth’s Campaign to Quiet Critics
The company has invoked the murder of an executive last year to complain about coverage in news outlets, on streaming services and on social media.
There’s now a chance for bipartisan health care policies, but partisan tensions are running high
A lot stands in the way of bipartisan health care policymaking, threatening PBM reform and extenders.
Use of antibiotic to reduce STIs appears to be fueling some antibiotic resistance, research shows
The use of the antibiotic doxycycline to reduce STIs appears to be fueling some antibiotic resistance, according to new research.
FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.
Academic groups finalize counterproposal to Trump’s research overhead cuts
A coalition of academic organizations has finalized a proposed alternative to the Trump administration’s plan to cut billions of dollars in research